TAVR in low-risk patients with symptomatic severe tricuspid aortic stenosis was safe and durable, with a 5.8% rate of structural valve deterioration at 4 years unaffected by 30-day HALT.
Cohort
Yes
Does TAVR provide safe and durable outcomes at 4 years in low-risk patients with symptomatic severe tricuspid aortic stenosis, and does 30-day hypoattenuated leaflet thickening (HALT) impact structural valve deterioration?
In low-risk patients with symptomatic severe tricuspid aortic stenosis, TAVR demonstrates safety and durability at 4 years, with 30-day subclinical leaflet thrombosis (HALT) showing no impact on long-term structural valve deterioration or clinical outcomes.
p-value: p==0.23
BACKGROUND: The LRT trial (Low-Risk Transcatheter Aortic Valve Replacement TAVR) demonstrated the safety and feasibility of TAVR in low-risk patients, with excellent 1- and 2-year outcomes. The objective of the current study is to provide the overall clinical outcomes and the impact of 30-day hypoattenuated leaflet thickening (HALT) on structural valve deterioration at 4 years. METHODS: The prospective, multicenter LRT trial was the first Food and Drug Administration-approved investigational device exemption study to evaluate feasibility and safety of TAVR in low-risk patients with symptomatic severe tricuspid aortic stenosis. Clinical outcomes and valve hemodynamics were documented annually through 4 years. RESULTS: =0.23) at 4 years. The overall rate of structural valve deterioration was 5.8%, and there was no impact of HALT on valve hemodynamics, endocarditis, or stroke at 4 years. CONCLUSIONS: TAVR in low-risk patients with symptomatic severe tricuspid aortic stenosis was found to be safe and durable at 4 years. Structural valve deterioration rates were low irrespective of the type of valve, and the presence of HALT at 30 days did not affect structural valve deterioration, transcatheter valve hemodynamics, and stroke rate at 4 years. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02628899.
Waksman et al. (Mon,) conducted a cohort in symptomatic severe tricuspid aortic stenosis. Transcatheter Aortic Valve Replacement (TAVR) was evaluated on structural valve deterioration at 4 years (p==0.23). TAVR in low-risk patients with symptomatic severe tricuspid aortic stenosis was safe and durable, with a 5.8% rate of structural valve deterioration at 4 years unaffected by 30-day HALT.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: